North America Meningococcal Vaccines Market Size & Outlook
The meningococcal vaccines market in North America is expected to reach a projected revenue of US$ 2,965.7 million by 2033. A compound annual growth rate of 3.2% is expected of North America meningococcal vaccines market from 2026 to 2033.
North America meningococcal vaccines market highlights
The North America meningococcal vaccines market generated a revenue of USD 2,236.6 million in 2025.
The market is expected to grow at a CAGR of 3.2% from 2026 to 2033.
In terms of segment, menveo was the largest revenue generating brand in 2025.
Nimenrix is the most lucrative brand segment registering the fastest growth during the forecast period.
Country-wise, Mexico is expected to register the highest CAGR from 2026 to 2033.
North America data book summary
Market revenue in 2025
USD 2,236.6 million
Market revenue in 2033
USD 2,965.7 million
Growth rate
3.2% (CAGR from 2026 to 2033)
Largest segment
Menveo
Fastest growing segment
Nimenrix
Historical data covered
2021 - 2024
Base year for estimation
2025
Forecast period covered
2026 - 2033
Quantitative units
Revenue in USD million
Market segmentation
Menactra, Menveo, Nimenrix, Trumenba, Bexsero
Key market players worldwide
Pfizer Inc, Sanofi SA, GSK PLC, Merck & Co Inc, Serum Institute of India Pvt. Ltd., Walvax Biotechnology
Other key industry trends
In terms of revenue, North America region accounted for 55.2% of the global meningococcal vaccines market in 2025.
Globally, North America is projected to lead the regional market in terms of revenue in 2033.
Asia Pacific is the fastest growing regional market and is projected to reach USD 1,007.4 million by 2033.
North America held the largest revenue share as it has highly regulated & well-developed healthcare infrastructure. Increasing access of vaccines through technology transfer and increasing local production of vaccines are anticipated to drive the market in the region.
Moreover, various campaigns and awareness programs are organized by charitable & nonprofit organizations such as National Meningitis Association (NMA), Meningitis Research Foundation of Canada, and Meningitis B Action Project, among others.
For instance, Meningitis Research Foundation of Canada conducts fund raising programs for research and raise awareness to support patients with meningitis, whereas the NMA educate healthcare professionals, public, & others about the disease and its prevention to protect families from the devastating effects of meningococcal disease.
North America Meningococcal Vaccines Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Meningococcal Vaccines Market Outlook will help companies and investors design strategic landscapes.
Menveo was the largest segment with a revenue share of 31.8% in 2025.
Horizon Databook has segmented the North America meningococcal vaccines market based on menactra, menveo, nimenrix, trumenba, bexsero covering the revenue growth of each sub-segment from 2021 to 2033.
North America held the largest revenue share as it has highly regulated & well-developed healthcare infrastructure. Increasing access of vaccines through technology transfer and increasing local production of vaccines are anticipated to drive the market in the region.
Moreover, various campaigns and awareness programs are organized by charitable & nonprofit organizations such as National Meningitis Association (NMA), Meningitis Research Foundation of Canada, and Meningitis B Action Project, among others.
For instance, Meningitis Research Foundation of Canada conducts fund raising programs for research and raise awareness to support patients with meningitis, whereas the NMA educate healthcare professionals, public, & others about the disease and its prevention to protect families from the devastating effects of meningococcal disease.
North America Meningococcal Vaccines Market Brand Outlook (Revenue, USD Million , 2021-2033)
Menactra
Menveo
Nimenrix
Trumenba
Bexsero
Others
North America Meningococcal Vaccines Market Serotype Outlook (Revenue, USD Million , 2021-2033)
A
B
C
W-135
Y
North America Meningococcal Vaccines Market Age Group Outlook (Revenue, USD Million , 2021-2033)
Infants (0 to 2 years)
Children and Adults (2 years and above)
North America Meningococcal Vaccines Market Sales Channel Outlook (Revenue, USD Million , 2021-2033)
Private
Public
North America Meningococcal Vaccines Market Type Outlook (Revenue, USD Million , 2021-2033)
Bivalent
Quadrivalent
Others
Reasons to subscribe to Meningococcal Vaccines Market Outlook databook
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Meningococcal Vaccines Market Outlook databook
Our clientele includes a mix of Meningococcal Vaccines Market Outlook companies, investment firms, advisory firms & academic institutions.
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the North America Meningococcal Vaccines Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into North America Meningococcal Vaccines Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
North America Meningococcal Vaccines Market, 2021-2033 (US$M)